GRI Bio Reports Increased R&D Spending Amid Higher Q1 Losses and Cash Reserve Decline

GRI Bio, Inc. (NASDAQ: VLON) has recently provided an update on its financial performance for the quarter ending March 31, 2025.

Positive Aspects:

• Research and Development Focus: GRI Bio is actively developing innovative therapies aimed at inflammatory and autoimmune diseases, with promising clinical candidates like GRI-0621.
• Increased R&D Spending: Operating expenses grew as the company invested more in research, with R&D expenses reaching $1.64 million, up from $0.93 million year-over-year, indicating a commitment to advancing their projects.
• Regulatory Progress: The FDA has cleared the IND application for GRI-0621, allowing GRI Bio to advance in clinical trials, which may lead to potential revenue streams.
• Recent Capital Raise: The company successfully raised gross proceeds of $5 million from the April 2025 public offering of common stock, helping to shore up its financial position.

Negative Aspects:

• Net Loss: GRI Bio reported a net loss of $3.05 million in Q1 2025, compared to a loss of $1.89 million in Q1 2024, indicating increasing burn rates as the company scales.
• Accumulated Deficit: The total accumulated deficit now stands at $42.79 million, raising concerns about long-term sustainability without additional funding.
• Decreasing Cash Reserves: Cash and cash equivalents decreased to $3.28 million from $5.03 million, reducing their liquidity cushion as they face ongoing operational losses.
• Increased Operating Expenses: Total operating expenses rose to $3.05 million, up from $1.90 million, driven by both R&D and administrative costs.

Key Financial Statistics:

• Operating Expenses:
  • R&D: $1.64 million (2025), $0.93 million (2024)
  • General and Administrative: $1.41 million (2025), $0.96 million (2024)
• Total Operating Loss: $3.05 million (2025), $1.89 million (2024)
• Net Loss: $3.05 million (2025), $1.89 million (2024)
• Net Loss Per Share: $5.80 (2025), $101.05 (2024)
• Weighted Average Shares Outstanding: 525,447 (2025), 18,665 (2024)

GRI Bio remains in a critical phase as it navigates its clinical trials while managing an accumulated deficit. The focus going forward will be on bolstering its cash position and improving operational efficiencies while advancing its promising therapeutic candidates.